GlassScriptPhysician profile
Elizabeth Fairless
NPI 1679100192
$1,791.45
in general payments reported to CMS, 2019-2025
18 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $361 · 2023: $640 · 2024: $171 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $621.58 | 2021-2024 | Clareon, Hydrus Microstent, Centurion |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $158.54 | 2021 | |
| Neurotech Pharmaceuticals, INC. | $139.09 | 2025 | |
| Horizon Therapeutics Plc | $110.88 | 2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $97.21 | 2025 | Iluvien |
| Abbvie INC. | $90.06 | 2022-2025 | |
| Ocular Therapeutix, INC. | $85.74 | 2022 | |
| New World Medical,INC. | $82.05 | 2023 | |
| Carl Zeiss Meditec USA, INC. | $67.02 | 2024 | |
| Bausch & Lomb Americas INC. | $63.90 | 2022-2024 | Stellaris |
| Glaukos Corporation | $53.82 | 2023 | |
| Merz Pharmaceuticals, LLC | $46.67 | 2023 | Xeomin |
| Depuy Synthes Sales INC. | $37.99 | 2023 | Synpor |
| Sight Sciences, INC. | $36.77 | 2024 | Omni Surgical System |
| Apellis Pharmaceuticals, INC. | $33.42 | 2025 | Syfovre |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $24.28 | 2022 | |
| Dutch Ophthalmic, USA | $23.16 | 2024 | Eva, Combined Machine, Tissueblue |
| Genentech USA, INC. | $19.27 | 2025 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Fairless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.